Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet activating factor acetylhydrolase (PAF-AH) or phospholipase A2 group 7 (PLA2G7), hydrolyzes glycerophospholipids to produce lyso-PAF/lyso-phosphatidylcholine and short and/or oxidized fatty acids, many of which have pro-inflammatory or pro-oxidative activities.1,2 Darapladib is a reversible inhibitor of Lp-PLA2 (IC50 = 0.25 nM).3 It produces sustained inhibition of plasma Lp-PLA2 activity in humans receiving intensive atorvastatin therapy.4 Lp-PLA2 inhibition with darapladib also reduces the development of coronary atherosclerotic plaques.5,6
WARNING This product is not for human or veterinary use.
1. .
2. .
3. .
4. .
5. .
6. .